Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BLLN affiliate files Form 144 to report proposed resale of Class A shares. The notice lists multiple blocks of Pre-IPO Class A shares dated 01/07/2020, 05/05/2020, and 07/03/2020 totaling discrete lots of 6,582, 3,200, and 800 shares respectively. The filing also discloses a sale in the past three months by Nancy J. Johnson of 3,418 Class A shares for $339,347.28 on 06/08/2026.
NeoTribe-affiliated funds and entities, each a 10% owner of BillionToOne, Inc., reported internal restructuring transactions in Class A Common Stock. On May 11, 2026, they executed J-code “other” transactions totaling 465,607 shares, classified as pro-rata, in-kind distributions to partners and members for no additional consideration.
These moves shifted shares among related funds and their investors at a stated price of $0.00 per share, changing how holdings are allocated between direct and indirect ownership but not reflecting open-market purchases or sales of BLLN stock.
BillionToOne director and ten percent owner Krishna Kittu Kolluri reported multiple internal restructuring transactions involving Class A Common Stock of BillionToOne, Inc. All 16 entries use transaction code J, reflecting other acquisitions or dispositions rather than open-market buys or sells.
The footnotes explain that NeoTribe investment funds, special purpose vehicles, and related entities made pro-rata, in-kind distributions of shares to partners, members, assignees, and family trusts for no additional consideration. The reported securities are held indirectly through these entities, and Kolluri generally disclaims beneficial ownership beyond his pecuniary interest.
BillionToOne, Inc. reported a sharp turnaround in Q1 2026, moving to profitability as revenue and test volumes scaled rapidly. Revenue rose to $108.4 million from $59.0 million a year earlier, driven by higher volumes and better pricing, especially in prenatal testing. Net income reached $18.0 million versus a prior-year loss of $4.0 million, and gross margin expanded to 73% from 64%.
Prenatal testing generated $96.5 million of revenue, oncology tests contributed $10.7 million, and clinical trial and other services added $1.1 million. Delivered and billable test volume grew to about 188,000 from 131,000. Operating cash flow improved to $15.4 million, while cash and cash equivalents increased to $537.5 million, supported by a new $30.0 million term loan tranche that lifted the fair value of long‑term debt to $90.0 million.
BillionToOne, Inc. reported sharply higher first quarter 2026 results, with total revenue of $108.4 million, up 84% from the first quarter of 2025. Growth was driven by a 44% increase in tests delivered and a 28% rise in overall average selling price.
Prenatal testing revenue reached $96.5 million, up 72%, while oncology testing revenue was $10.7 million, more than four times the prior year. Gross margin improved to 73% from 64%, supporting income from operations of $17.8 million versus a loss a year earlier. Net income was $17.97 million, or $0.34 per diluted share. The company raised its 2026 revenue outlook to a range of $450 million to $465 million, implying 48% to 52% growth over 2025, and expects to maintain profitability near current levels while continuing to invest.